Kristin Huntoon1,2, Tianxia Wu3, J Bradley Elder1, John A Butman4, Emily Y Chew5, W Marston Linehan6, Edward H Oldfield2,7, Russell R Lonser1,2. 1. Department of Neurological Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio; 2. Surgical Neurology Branch and. 3. Office of the Clinical Director, National Institute of Neurological Disorders and Stroke; 4. Neuroradiology Section, Diagnostic Radiology, Clinical Center at the National Institutes of Health; 5. Division of Epidemiology and Clinical Applications, National Eye Institute; 6. Urologic Oncology Branch, Center for Cancer Research, National Institutes of Health, Bethesda, Maryland; and. 7. Department of Neurological Surgery, University of Virginia Health Sciences Center, Charlottesville, Virginia.
Abstract
OBJECTIVE: Peritumoral cysts are frequently associated with CNS hemangioblastomas and often underlie neurological morbidity and mortality. To determine their natural history and clinical impact, the authors prospectively analyzed hemangioblastoma-associated peritumoral cysts in patients with von Hippel-Lindau (VHL) disease. METHODS: Patients with VHL disease who had 2 or more years of follow-up and who were enrolled in a prospective study at the National Institutes of Health were included. Serial prospectively acquired laboratory, genetic, imaging, and clinical data were analyzed. RESULTS: One hundred thirty-two patients (of 225 in the VHL study with at least 2 years of follow-up) had peritumoral cysts that were followed for more than 2 years (total of 292 CNS peritumoral cysts). The mean age at study entrance was 37.4 ± 13.1 years ([mean ± SD], median 37.9, range 12.3-65.1 years). The mean follow-up was 7.0 ± 1.7 years (median 7.3, range 2.1-9.0 years). Over the study period, 121 of the 292 peritumoral cysts (41.4%) became symptomatic. Development of new cysts was associated with a larger number cysts at study enrollment (p = 0.002) and younger age (p < 0.0001). Cyst growth rate was associated with anatomical location (cerebellum cysts grew faster than spine and brainstem cysts; p = 0.0002 and p = 0.0008), younger age (< 35 years of age; p = 0.0006), and development of new neurological symptoms (p < 0.0001). Cyst size at symptom production depended on anatomical location (p < 0.0001; largest to smallest were found, successively, in the cerebellum, spinal cord, and brainstem). The most common location for peritumoral cysts was the cerebellum (184 cysts [63%]; p < 0.0001). CONCLUSIONS: Peritumoral cysts frequently underlie symptom formation that requires surgical intervention in patients with VHL disease. Development of new cysts was associated with a larger number of cysts at study enrollment and younger age. Total peritumoral cyst burden was associated with germline partial deletion of the VHL gene.
OBJECTIVE: Peritumoral cysts are frequently associated with CNS hemangioblastomas and often underlie neurological morbidity and mortality. To determine their natural history and clinical impact, the authors prospectively analyzed hemangioblastoma-associated peritumoral cysts in patients with von Hippel-Lindau (VHL) disease. METHODS:Patients with VHL disease who had 2 or more years of follow-up and who were enrolled in a prospective study at the National Institutes of Health were included. Serial prospectively acquired laboratory, genetic, imaging, and clinical data were analyzed. RESULTS: One hundred thirty-two patients (of 225 in the VHL study with at least 2 years of follow-up) had peritumoral cysts that were followed for more than 2 years (total of 292 CNS peritumoral cysts). The mean age at study entrance was 37.4 ± 13.1 years ([mean ± SD], median 37.9, range 12.3-65.1 years). The mean follow-up was 7.0 ± 1.7 years (median 7.3, range 2.1-9.0 years). Over the study period, 121 of the 292 peritumoral cysts (41.4%) became symptomatic. Development of new cysts was associated with a larger number cysts at study enrollment (p = 0.002) and younger age (p < 0.0001). Cyst growth rate was associated with anatomical location (cerebellum cysts grew faster than spine and brainstem cysts; p = 0.0002 and p = 0.0008), younger age (< 35 years of age; p = 0.0006), and development of new neurological symptoms (p < 0.0001). Cyst size at symptom production depended on anatomical location (p < 0.0001; largest to smallest were found, successively, in the cerebellum, spinal cord, and brainstem). The most common location for peritumoral cysts was the cerebellum (184 cysts [63%]; p < 0.0001). CONCLUSIONS: Peritumoral cysts frequently underlie symptom formation that requires surgical intervention in patients with VHL disease. Development of new cysts was associated with a larger number of cysts at study enrollment and younger age. Total peritumoral cyst burden was associated with germline partial deletion of the VHL gene.
Entities:
Keywords:
IQR = interquartile range; ROC = receiver operating characteristic; VHL = von Hippel-Lindau; central nervous system; cyst; hemangioblastoma; natural history; oncology; treatment; von Hippel-Lindau disease
Authors: I R Maddock; A Moran; E R Maher; M D Teare; A Norman; S J Payne; R Whitehouse; C Dodd; M Lavin; N Hartley; M Super; D G Evans Journal: J Med Genet Date: 1996-02 Impact factor: 6.318
Authors: S Richard; D Chauveau; Y Chrétien; C Beigelman; A Denys; J P Fendler; G Fromont; F Paraf; O Hélénon; S Nizard Journal: Adv Nephrol Necker Hosp Date: 1994
Authors: C Stolle; G Glenn; B Zbar; J S Humphrey; P Choyke; M Walther; S Pack; K Hurley; C Andrey; R Klausner; W M Linehan Journal: Hum Mutat Date: 1998 Impact factor: 4.878
Authors: R A Berkman; M J Merrill; W C Reinhold; W T Monacci; A Saxena; W C Clark; J T Robertson; I U Ali; E H Oldfield Journal: J Clin Invest Date: 1993-01 Impact factor: 14.808
Authors: H P Neumann; H R Eggert; R Scheremet; M Schumacher; M Mohadjer; A K Wakhloo; B Volk; U Hettmannsperger; P Riegler; P Schollmeyer Journal: J Neurol Neurosurg Psychiatry Date: 1992-10 Impact factor: 10.154
Authors: Russell R Lonser; Gladys M Glenn; McClellan Walther; Emily Y Chew; Steven K Libutti; W Marston Linehan; Edward H Oldfield Journal: Lancet Date: 2003-06-14 Impact factor: 79.321
Authors: Eric Jonasch; Ian E McCutcheon; Dan S Gombos; Kamran Ahrar; Nancy D Perrier; Diane Liu; Christine C Robichaux; Mercedes F Villarreal; Justin A Weldon; Ashley H Woodson; Patrick G Pilie; Gregory N Fuller; Steven G Waguespack; Surena F Matin Journal: Lancet Oncol Date: 2018-09-17 Impact factor: 41.316
Authors: Gautam U Mehta; Blake K Montgomery; Dominic M Maggio; Prashant Chittiboina; Edward H Oldfield; Russell R Lonser Journal: Oper Neurosurg (Hagerstown) Date: 2017-08-01 Impact factor: 2.703
Authors: J Crespigio; L C L Berbel; M A Dias; R F Berbel; S S Pereira; D Pignatelli; T L Mazzuco Journal: J Endocrinol Invest Date: 2017-06-06 Impact factor: 4.256
Authors: Jan-Helge Klingler; Sven Gläsker; Birke Bausch; Horst Urbach; Tobias Krauss; Cordula A Jilg; Christine Steiert; Alexander Puzik; Elke Neumann-Haefelin; Fruzsina Kotsis; Hansjürgen Agostini; Hartmut P H Neumann; Jürgen Beck Journal: Childs Nerv Syst Date: 2020-06-07 Impact factor: 1.475